Weekly Recap: Zilebesiran Phase 2 BP drop and 2026 TTR guidance cut
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) rode AMVUTTRA’s strong launch and expanding access while zilebesiran showed Phase 2 BP benefit as Phase 3 ZENITH enrolls 11,000 patients; company trimmed 2026 TTR revenue guidance but HC Wainwright stays Buy, citing RNAi pipeline strength.Previous Week Rec…